CA3019841A1 - Methods and compositions for the prevention and treatment of surgical adhesions - Google Patents

Methods and compositions for the prevention and treatment of surgical adhesions Download PDF

Info

Publication number
CA3019841A1
CA3019841A1 CA3019841A CA3019841A CA3019841A1 CA 3019841 A1 CA3019841 A1 CA 3019841A1 CA 3019841 A CA3019841 A CA 3019841A CA 3019841 A CA3019841 A CA 3019841A CA 3019841 A1 CA3019841 A1 CA 3019841A1
Authority
CA
Canada
Prior art keywords
adhesion
agent
adhesions
formation
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3019841A
Other languages
English (en)
French (fr)
Inventor
Jonathan Tsai
Nathaniel FERNHOFF
Rahul Sinha
Yuval Rinkevich
Irving L. Weissman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA3019841A1 publication Critical patent/CA3019841A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
CA3019841A 2016-04-29 2017-05-01 Methods and compositions for the prevention and treatment of surgical adhesions Pending CA3019841A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329666P 2016-04-29 2016-04-29
US62/329,666 2016-04-29
PCT/US2017/030454 WO2017190148A1 (en) 2016-04-29 2017-05-01 Methods and compositions for the prevention and treatment of surgical adhesions

Publications (1)

Publication Number Publication Date
CA3019841A1 true CA3019841A1 (en) 2017-11-02

Family

ID=60161169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3019841A Pending CA3019841A1 (en) 2016-04-29 2017-05-01 Methods and compositions for the prevention and treatment of surgical adhesions

Country Status (9)

Country Link
US (1) US10934355B2 (https=)
EP (1) EP3448421B1 (https=)
JP (1) JP7160683B2 (https=)
CA (1) CA3019841A1 (https=)
ES (1) ES2903210T3 (https=)
PL (1) PL3448421T3 (https=)
PT (1) PT3448421T (https=)
SI (1) SI3448421T1 (https=)
WO (1) WO2017190148A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115645396A (zh) * 2020-02-26 2023-01-31 上海科技大学 丙基-2-咪唑二硫醚在抗冠状病毒中的应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
EP3917515A1 (en) 2019-01-29 2021-12-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
US20200386772A1 (en) * 2019-06-05 2020-12-10 Mark D. Noar Method For Detecting Bodily Adhesions By Identifying Markers In Circulating Cells
WO2022126259A1 (en) * 2020-12-14 2022-06-23 Uti Limited Partnership Treatment of peritoneal, pleural, and pericardium adhesions
US20220233135A1 (en) * 2021-01-22 2022-07-28 Ethicon Llc Prediction of adhesions based on biomarker monitoring
US12543982B2 (en) 2021-01-22 2026-02-10 Cilag Gmbh International Method of adjusting a surgical parameter based on biomarker measurements
US12011163B2 (en) 2021-01-22 2024-06-18 Cilag Gmbh International Prediction of tissue irregularities based on biomarker monitoring
US12440285B2 (en) 2021-01-22 2025-10-14 Cilag Gmbh International Prediction of hemostasis issues based on biomarker monitoring
CN113244400B (zh) * 2021-05-21 2022-12-16 华北理工大学 一种C5aRA在制备治疗和/或预防腹腔粘连的产品中的应用
KR20240099431A (ko) * 2021-11-05 2024-06-28 헬름홀츠 젠트룸 뮌헨-도이체스 포르슝스젠트룸 퓌르 게준드하이트 운트 움벨트 게엠베하 중피 ecm 이동의 조절제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639468A (en) 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof
JP2001520201A (ja) 1997-10-16 2001-10-30 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 癒着形成の予防と処置
US6812220B2 (en) 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
DE60310383T2 (de) 2002-01-29 2007-09-20 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Vorbeugung von gewebeadhäsion
US20040131600A1 (en) 2002-03-11 2004-07-08 Diamond Michael P. Method of preventing adhesions by apoptosis of adhesion peritoneal cells
JP4224586B2 (ja) 2004-04-28 2009-02-18 国立大学法人群馬大学 マクロファージ活性化剤並びにその製造方法及びスクリーニング方法
US20080045463A1 (en) 2004-10-25 2008-02-21 Ajay Verma Methods For Lowering Hif-1 Mediated Gene Expression
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
EP1891141B1 (en) 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblock copolymers for cytoplasmic delivery of gene-based drugs
PT1940439E (pt) 2005-08-11 2010-12-17 Univ Saskatchewan Redução da formação de aderências pós-operatórias com glutamina intraperitoneal
CA2658584A1 (en) * 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
CA2700860C (en) * 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
AU2009205665B2 (en) 2008-01-15 2013-12-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
ES2325724B1 (es) 2008-03-11 2010-05-31 FUNDACION DE LA COMUNIDAD VALENCIANA "CENTRO DE INVESTIGACIONES PRINCIPE FELIPE" Composicion farmaceutica para inhibir el factor de transcripcion inducible por hipoxia. moduladores de procesos patologicos de angiogenesis, oncogenesis, inflamacion, apoptosis y terapia celular.
US8460660B2 (en) * 2009-03-24 2013-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
EP2477648B1 (en) 2009-09-15 2022-07-20 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
JP2011195574A (ja) 2010-02-25 2011-10-06 Kwansei Gakuin ビスフェノールａ誘導体を含有するｈｉｆ阻害剤
SI2804617T1 (sl) * 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
PT2970493T (pt) 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115645396A (zh) * 2020-02-26 2023-01-31 上海科技大学 丙基-2-咪唑二硫醚在抗冠状病毒中的应用

Also Published As

Publication number Publication date
EP3448421B1 (en) 2021-11-03
US10934355B2 (en) 2021-03-02
JP2019514913A (ja) 2019-06-06
SI3448421T1 (sl) 2022-02-28
US20190048077A1 (en) 2019-02-14
JP7160683B2 (ja) 2022-10-25
EP3448421A1 (en) 2019-03-06
PT3448421T (pt) 2022-01-14
ES2903210T3 (es) 2022-03-31
EP3448421A4 (en) 2019-12-25
WO2017190148A1 (en) 2017-11-02
PL3448421T3 (pl) 2022-03-28

Similar Documents

Publication Publication Date Title
EP3448421B1 (en) Methods and compositions for the prevention and treatment of surgical adhesions
Headland et al. Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma
Li et al. Endometriotic mesenchymal stem cells significantly promote fibrogenesis in ovarian endometrioma through the Wnt/β-catenin pathway by paracrine production of TGF-β1 and Wnt1
Shaikh et al. A signaling pathway map of plasminogen activator inhibitor-1 (PAI-1/SERPINE-1): a review of an innovative frontier in molecular aging and cellular senescence
Zheng et al. The presence of Prevotella melaninogenica within tissue and preliminary study on its role in the pathogenesis of oral lichen planus
US12582696B2 (en) Debaryomyces species as an indicator of non-healing ulcers in Crohn's disease
EP4168001B1 (en) An inhibitor of the activator protein 1 (ap-1) for preventing and treating adhesions
Liu et al. The KLF4/Galectin-3 cascade is a key determinant of tubular cell death and acute kidney injury
EP3586840B1 (en) Mmp7 inhibitors for use in treating cystitis
Wu et al. Eosinophil-derived interleukin-24 compromises epithelial integrity and aggravates airway remodeling in mouse models of allergic asthma
He et al. Administration of exogenous fractalkine, a CX3C chemokine, is capable of modulating inflammatory response in cecal ligation and puncture-induced sepsis
Cha et al. Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis
HUANG et al. Murphy
Liebold The interplay between apoptotic cells and macrophages: impact on the phenotype and function of macrophages
US20250255932A1 (en) Granulocyte-Colony Stimulating Factor For The Promotion Of Scarless Tissue Regeneration
Khan Developing physiological 3D in vitro tissue models for rheumatology research
Jacobs et al. The role of eosinophils in intestinal inflammation and fibrosis in inflammatory bowel disease.
WO2017127830A1 (en) Anti-neutrophil activity on innate immune response
EP4525929A1 (en) Methods and compositions for treating or preventing inflammatory skin disorders
Watt Dissecting the role of TGFβ in pancreatic ductal adenocarcinoma
Orsi CHARACTERIZATION OF A NEW INTERMEDIATE MACROPHAGE SUBPOPULATION: SDC-1-POSITIVE SPM-LIKE MACROPHAGES POSSESS IMMUNOSUPPRESSIVE FUNCTIONS IN EARLY MESOTHELIOMAGENIC RESPONSES TO CARBON NANOTUBES
Baer Tissue Resident Macrophages Drive Fibrosis During Pancreas Inflammatory Injury and Pancreatic Ductal Adenocarcinoma
Blackburn Surgery, Science, and the Models that Fall in Between: A Foray into Intra-Cavitary Adhesions
CN121445871A (zh) 一种靶向衰老b细胞治疗系统性红斑狼疮的方法和应用
Friscic Synovial Fibroblasts Shape Local Inflammatory Responses in the Joint

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220426

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240724

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250129

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250526

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250526

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251216